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Supporting prescribing in older people
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cluster randomised controlled trial protocol
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Abstract
Background: Multimorbidity, defined as the presence of at least two chronic conditions, becomes increasingly
common in older people and is associated with poorer health outcomes and significant polypharmacy. The
National Institute for Clinical Excellence (NICE) recently published a multimorbidity guideline that advises providing
an individualised medication review for all people prescribed 15 or more repeat medicines. This study incorporates
this guideline and aims to assess the effectiveness of a complex intervention designed to support general
practitioners (GPs) to reduce potentially inappropriate prescribing and consider deprescribing in older people with
multimorbidity and significant polypharmacy in Irish primary care.
Methods: This study is a cluster randomised controlled trial, involving 30 general practices and 450 patients
throughout Ireland. Practices will be eligible to participate if they have at least 300 patients aged 65 years and over
on their patient panel and if they use either one of the two predominant practice management software systems
in use in Ireland. Using a software patient finder tool, practices will identify and recruit patients aged 65 years and
over, who are prescribed at least 15 repeat medicines. Once baseline data collection is complete, practices will be
randomised using minimisation by an independent third party to either intervention or control. Given the nature of
the intervention, it is not possible to blind participants or study personnel. GPs in intervention practices will receive
login details to a website where they will access training videos and a template for conducting an individualised
structured medication review, which they will undertake with each of their included patients. Control practices will
deliver usual care over the 6-month study period. Primary outcome measures pertain to the individual patient level
and are the proportion of patients with any PIP and the number of repeat medicines.
Discussion: Disease-specific approaches in multimorbidity may be inappropriate and result in fragmented and
poorly co-ordinated care. This pragmatic study is evaluating a complex intervention that is relevant across multiple
conditions and addresses potential concerns around medicines safety in this vulnerable group of patients. The
potential for system-wide implementation will be explored with a parallel mixed methods process evaluation.
Trial registration: ISRCTN: 12752680, Registered 20 October 2016.
Keywords: Complex intervention, Multimorbidity, Polypharmacy, Potentially inappropriate prescribing (PIP),
Deprescribing, Patient priorities, Randomised controlled trial
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Background
Advances in public health and health care have led to
increases in life expectancy and a resultant rising popu-
lation of older people living with multiple long-term
conditions or multimorbidity, now estimated to be at
least 60% for those over 65 years [1]. There is a growing
consensus that the current single disease model of
healthcare, which arose out of specialisation, may not be
appropriate when managing these patients and may
result in fragmented care and significant treatment bur-
den for patients [2, 3]. Providing optimal care for these
patients is challenging, considering their heterogeneity
and the lack of evidence for the effectiveness of many
treatments, due to exclusion of these patients from ran-
domised controlled trials [4]. A systematic review look-
ing at interventions to improve outcomes in patients
with multimorbidity concluded that targeting risk factors
or specific functional difficulties may be most effective
[5]. The recently published National Institute for Health
and Care Excellence (NICE) guideline, “Multimorbidity:
assessment, prioritisation and management of care for
people with commonly occurring multimorbidity” identifies
the link between complex multimorbidity and polyphar-
macy and advises targeting patients who are prescribed ≥15
repeat medicines and providing a tailored or individualised
structured medication review [6].
In line with rising levels of multimorbidity, the preva-
lence of significant polypharmacy is steadily rising. Re-
cent longitudinal analysis indicates that approximately
5% of Irish people aged over 65 years are prescribed 15
or more repeat medicines [7]. Polypharmacy is associ-
ated with a multitude of adverse outcomes including ad-
verse drug reactions (ADRs), medication errors, reduced
adherence, increased cost and increased morbidity and
mortality [4, 8, 9]. ADRs are a significant burden to the
health system and it is estimated that over 10% of emer-
gency hospital admissions in older patients may be
ADR-related [10]. ADRs have also been described as the
“great mimic of systemic disease” [11] and often result
in a prescribing cascade, where more medication is used
to treat the side effects of another [12]. In patients with
multimorbidity, polypharmacy may often be appropriate,
however, it is the strongest risk factor for potentially in-
appropriate prescribing (PIP), a term used to describe sub-
optimal prescribing practices where the risks of treatment
usually outweigh the benefits [13].
Various tools have been developed to both tackle and
measure PIP, including explicit measures of appropriate-
ness such as the United States (US) Beers criteria [14]
and the European Screening Tool for Older People’s po-
tentially inappropriate Prescriptions (STOPP) criteria
[15]. Explicit measures of medication appropriateness
have been demonstrated to be effective at improving
prescribing and have the advantage of being relatively
reproducible, reliable and easy to apply to large numbers
of people [16]; however, they do not account for individ-
ual patient characteristics and preferences. Implicit
measures such the Medication Appropriateness Index
[17] involve clinician judgement and do account for pa-
tient characteristics, however, they are time-consuming
and complex to apply, and generally involve a detailed
assessment of the effectiveness and appropriateness of
each prescribed medication [4]. Several systematic re-
views have assessed various approaches, including the
use of explicit and implicit measures of appropriateness,
to tackling inappropriate polypharmacy [18–21] with the
over-riding conclusion that inappropriate polypharmacy
is amenable to change but that a multifaceted approach
is likely to be more effective.
Improvements in computerised clinical decision support
systems, where individual patient data are inputted into a
computer program, sorted and matched using algorithms
generated from a prior knowledge base resulting in patient-
specific recommendations [22], may ultimately prove effect-
ive in optimising medication for this complex group of
patients. An on-going European Union (EU) funded project
is developing a highly powered and efficient software en-
gine that will be able to individually screen the medication
of older patients with multimorbidity and provide recom-
mendations on optimal drug therapy and ADR risk [23].
Similarly Young et al. in New Zealand are validating and
piloting a set of prescribing decision tools that will be em-
bedded in practice management software (PMS) [24]. How-
ever, before such technology is demonstrated to be safe,
effective and feasible in daily practice, it is important to
continue to develop effective and pragmatic interventions
that can assist GPs in caring and prescribing for these
complex patients. We also argue that software-driven rec-
ommendations need to be accompanied by an assessment
of patients’ treatment priorities.
Despite recommendations advising tailoring care to pa-
tient priorities, there is very little in the literature on how
to best assess and record patient priorities. A systematic
review identified only one such tool that has been used
and validated in patients with multimorbidity [25, 26]. A
research group in Spain have recently published a protocol
for a RCT which will examine the effect of an individua-
lised medication review using a tool designed to aid the
physician in prioritising the patient’s problems on medica-
tion appropriateness [27]. However, the effectiveness,
feasibility and potential for negative effects of using these
tools in practice have not been established.
Rationale for SPPiRE trial
Our research group previously demonstrated that an
intervention comprising academic detailing and a web-
based prescribing support was effective in reducing
potentially inappropriate prescribing in older patients in
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Irish primary care, primarily through the reduction of
prescribing of proton pump inhibitors at maximal dose
(OPTI-SCRIPT trial) [34]. Supporting prescribing in
older patients with multimorbidity and significant poly-
pharmacy (SPPiRE) is a cluster RCT that will assess the
effectiveness of an intervention designed to reduce both
PIP and polypharmacy. The SPPiRE intervention evolved
based on the OPTI-SCRIPT trial results and process
evaluation [28, 29], emerging evidence in relation to
multimorbidity and polypharmacy [5, 6, 19, 20, 30] and
the NICE multimorbidity guideline described previously
[6]. In line with the Medical Research Council’s Frame-
work on developing and evaluating complex interven-
tions, the OPTI-SCRIPT intervention and trial were
adapted to develop the SPPiRE study (Fig. 1). The MRC
Framework describes an iterative process where piloting
work, process and outcome evaluations and other bodies
of emerging evidence feed back into the original inter-
vention design [31]. The target population and individ-
ual components of the intervention have been amended
(Table 1). Our proposed SPPiRE intervention will also
assess the effect on patient-reported outcome measures
(PROMs) of treatment burden and quality of life and
undertake a parallel qualitative evaluation, which will
provide important evidence on the patient experience.
Medication appropriateness will be examined using
explicit criteria and a tailored approach, where indi-
vidual patient priorities are addressed. Tailoring care
in this way minimises the harms of overtreatment by
prioritising treatments that are most important to the
patient [25, 32]. Explicit criteria have been selected
using the updated STOPP 2 criteria [15] and moni-
toring criteria developed and validated by the Data-
driven Quality Improvement in Primary care (DQIP)
research group [33], with a focus on drug classes that
are frequently implicated in preventable drug-related
morbidity (PDRM) [34] and criteria that were more
relevant for older people in Irish primary care (listed
in Tables 2, 3, and 4) during the development of our
previous OPTI-SCRIPT intervention [35]. The tool
will support GPs to identify PIPs for individual pa-
tients and then suggest potential treatment alterna-
tives in the context of patient priorities identified
during the process. As described previously, several
tools have recently been developed to assess patient
priorities, however, given uncertainty of the effective-
ness of these tools, we have opted to prompt the GP
to ask about and record individual priorities during
the medication review rather than trying to operation-
alise this process. The implementation and effect of
this novel aspect of the intervention will be further
explored in the parallel mixed methods process evalu-
ation. Reviewing medicines in the context of both
explicit measures of appropriateness and individual
patient priorities will ensure that medicines that are
potentially inappropriate, either because of ineffective-
ness in relation to symptom control, adverse effects
or unfavourable risk/benefit ratios are discontinued or
changed [4, 36, 37].
This paper aims to describe the results of a small-scale
uncontrolled pilot study of the SPPiRE intervention and
the final refinement of the intervention, as well as
present the protocol for the definitive randomised
controlled trial.
Trial objectives
The overall aim of this research is to evaluate the effect-
iveness of a complex intervention (SPPiRE), to support
GPs to improve the safety of their prescribing and to
reduce polypharmacy in patients aged 65 years or over
with multimorbidity and significant polypharmacy (15 or
more repeat medicines) in Irish primary care. The effect
of the intervention will be measured at the individual
patient level.
Fig. 1 Development and evaluation of SPPiRE, adapted from MRC framework [31]. Legend: Adaptation of the MRC framework showing the
evolution of the SPPiRE intervention based on previous outcome and process evaluations, piloting and feasibility work and emerging evidence
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Specific objectives are:
1. Undertake a definitive cluster randomised controlled
trial to evaluate the effectiveness of the multifaceted
SPPiRE intervention, comprising professional
education and a web-guided structured medication
review where patient priorities are assessed, in
reducing PIP and polypharmacy.
2. To determine the cost effectiveness of this intervention.
3. To explore the potential for system-wide implementation
of the SPPiRE intervention in Irish primary care through
a mixed methods process evaluation.
Table 1 Evolution of SPPiRE from OPTI-SCRIPT
OPTI-SCRIPT [28] SPPiRE
Population Research pharmacist determined if identified older patients
had a PIP
Identified by patient finder tool as being prescribed ≥15
repeat medicines
Intervention Academic detailing by research pharmacist Training video by research GP
Web-guided medication review
• Provided with alternative pharmaceutical treatment
algorithms for PIP
Web-guided medication review
• Guided to check for specific PIP
• Guided to tailor care to patient’s priorities
Primary outcomes Proportion of patients with PIP Proportion of patients with PIP
Mean number of PIPs per patient Number of repeat medications
Secondary outcomes Drug specific outcomes Medication changes
Patient-reported outcomes
• Quality of life
• Patient’s medication beliefs
• Patient well being
Patient-reported outcomes
• Quality of life
• Patient’s attitudes to deprescribing
• Treatment burden
Table 2 SPPiRE PIP; drug groups frequently implicated in preventable drug related morbidity [34]
Drug group PIP Reason
NSAIDS With diuretic and ACEi/ARB [33] Risk of renal impairment
With chronic kidney disease (eGFR <50 ml/min/ 1.73m2) [15, 33]
For ≥12 weeks with no gastroprotection [33] Risk of GI bleed
With a history of PUD with no gastroprotection [15]
and antiplatelet with no gastroprotection [15]
With an anticoagulant [15, 35]
With severe hypertension or heart failure [15] Risk of hypertension/heart failure exacerbation
COX-2 selective with concurrent cardiovascular disease [15] Increased risk of MI/CVA
Antiplatelets And history of PUD with no gastroprotection [33, 35] Risk of GI bleed
And anticoagulant with no gastroprotection [33, 35]
Aspirin and clopidogrel with no gastroprotection [33]
Consider intended duration of treatment if taking dual
anti-platelet therapy for over 1 year post PCI [15]
Not usually indicated
Anticoagulants For first uncomplicated DVT for >6 months duration [15] Not indicated
For first uncomplicated PE for >12 months duration [15]
Dabigatran if eGFR <30 ml/min/1.73m2 or if renal function is unknown [15] Risk of bleeding
Rivaroxaban or apixaban if eGFR <15 ml/min/1.73m2 or if renal function is
unknown [15]
Diuretics And no renal profile in the last 48 weeks [33] Risk of renal impairment and electrolyte abnormality
Loop diuretic and thiazide diuretic and no renal profile in the last
24 weeks [33]
Loop diuretic for dependent oedema and no heart failure, liver failure or
nephrotic syndrome [15]
Risks usually out weigh benefits
Thiazide diuretic with a history of gout [15] Risk of precipitating gout
Abbreviations: NSAID non-steroidal anti-inflammatory drug, ACEi angiotensin converting enzyme inhibitor, ARB aldosterone receptor blocker, eGFR estimated
glomerular filtration rate, PUD peptic ulcer disease, GI gastro-intestinal, MI myocardial infarction, CVA cerebrovascular accident, COX-2 cyclooxygenase-2, DVT deep
vein thrombosis, PCI percutaneous coronary intervention, PE pulmonary embolism
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Pilot study methods and results
Study design
A small-scale uncontrolled pilot study was undertaken
to assess the feasibility and acceptability of the adapted
SPPiRE intervention and to assess whether the interven-
tion needed further adaptation [38].
Study population
Six general practitioners, including four academic GPs,
one full-time clinical GP and one GP registrar piloted the
SPPiRE web-guided medication review with 10 different
patients.
Procedure
A SPPiRE software patient finder tool was developed to
allow GPs to easily identify all their patients aged ≥65 years
and prescribed ≥15 repeat medicines. This tool was
piloted by three GPs in three practices, as at the time of
the pilot it was only available in one of the two predomin-
ant PMS systems used in Ireland. A repeat medicine was
defined as any item that has an Anatomical Therapeutic
Chemical (ATC) code, is currently being prescribed to the
patient and is classified in the PMS as a “repeat” as op-
posed to “acute” item. GPs also have to manually screen
the generated list to ensure “acute” prescriptions have not
been inadvertently left on the “repeat” list.
All six GPs piloted the SPPiRE intervention and pro-
vided feedback to the trial manager (CMcC) on outcome
measures and the feasibility and acceptability of the
intervention. Each GP watched the SPPiRE training
videos and invited either one or two identified patients
for a medication review. The GPs logged onto the
SPPiRE website at the start of the medication review and
were guided through the medication review process. The
steps involved were:
 Counting the current number of repeat medicines
 Screening the current prescription for potentially
inappropriate prescriptions using supports provided
within the tool
 Assessing patient treatment priorities
 Reviewing each medicine with the patient to assess
effectiveness, side-effects and actual drug utilisation
 Agreeing changes with the patient, based on both
web-guided suggested alternatives and the patient’s
treatment priorities
Results
The feasibility of the finder tool and intervention were
assessed through GP feedback and analysis of use of the
online material. Overall, the intervention was well re-
ceived by the GPs and their patients many of whom
Table 3 SPPiRE PIP; drug groups associated with morbidity in the elderly [33]
Drug group PIP Reason
Anticholinergic drugs With comorbidities [35]
• Dementia
• Narrow angle glaucoma
• Cardiac conduction abnormalities
• Chronic prostatism
Exacerbation of comorbidity
Concomitant use of two or more drugs with
anticholinergic properties [15]
Risk of anticholinergic toxicity
Tricyclic antidepressant as first line antidepressant [15] Increased risk of adverse effects in older patients and
alternatives available
Antimuscarinic antihistamine [15]
Benzodiazipines OR Z drugs For longer than 4 weeks [15] [33] Risk of sedation, confusion, impaired balance, falls.
NNT 13 and NNH 6 when used for insomnia [57]
Antipsychotics With dementia and no psychosis [15, 33] Increased risk of stroke, only use when all other means have
failed and shortest possible dose for shortest duration [58]
Abbreviations: NNT number needed to treat, NNH number needed to harm
Table 4 SPPiRE PIP, miscellaneous
Drug group PIP Reason
Methotrexate Not prescribed as weekly [33] Increased risk of potentially fatal medication errors
Prescribed >1 strength tablet [33]
Opioids Used regularly with no laxative [15] Risk of severe constipation
Corticosteroids Used ≥12 weeks with no bone protection [15] Risk of fracture
PPI For uncomplicated PUD/erosive peptic oesophagitis
at full therapeutic dose ≥8 weeks [15]
Not indicated
Metformin With eGFR <30 ml/min/ 1.73m2 [15] Risk of lactic acidosis
Abbreviations: eGFR estimated glomerular filtration rate, PUD peptic ulcer disease
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reported feeling reassured that their medicines were
being reviewed and rationalised. There was a large vari-
ation between practices in the proportion of those aged
≥65 years detected by the finder tool (1.9–17%) which
may be partially explained by differences between prac-
tices in how prescription lists are kept up to date and
socio-demographic differences, both of which will be
identified by the practice profile questionnaire at base-
line for the main trial. Due to lack of universal registra-
tion of private patients in Irish general practice,
practices use varying approaches to count their private
patient panel. The differences in the finder tool detec-
tion rate may also reflect an inaccurate denominator,
where private patients aged ≥65 years are over counted
for example visitors and those who have moved.
Of the 10 patients who underwent the medication re-
view, they were prescribed an average of 17.5 medicines
(SD +/−3.41) and this reduced to 16.8 (SD +/−3.94) im-
mediately post-intervention. All of the included patients
had at least 1 PIP, with a mean of 1.8 per patient. The
most common PIP identified were the use of a “proton
pump inhibitor for uncomplicated PUD/erosive peptic
oesophagitis at full therapeutic dose for ≥8 weeks” (39%)
and the use of a “benzodiazepine or Z drug for longer
than 4 weeks” (39%). When the higher prevalence, lower
risk proton pump inhibitor PIP was excluded, 90% of
patients had at least 1 PIP and the mean number of PIP
per patient was 1.1. Identified instances of PIP were
acted on in 44% of cases and 45% when the proton
pump inhibitor PIP was excluded. The most commonly
reported patient treatment priorities were treating pain,
followed by fatigue and reducing the number of repeat
medicines.
Intervention modification
Based on the results described above, minor modifica-
tions were made to the training videos and the medica-
tion review template to make instruction more explicit
and reduce repetition (summarised in Table 5). The
finder tool was modified to only include items with a
unique ATC code to prevent different doses of the same
drug being counted twice. The need for the GP to
manually screen the generated list was evident, and
guidance on how to best do this was developed. The
review also took longer to implement than anticipated,
on average about 40 min and a recommendation to allow
for this amount time was added to the demonstration
video and support materials.
Methods: Protocol for the SPPiRE trial
Study design
A pragmatic two-arm cluster randomised controlled trial
will be conducted. The study design was developed in
line with the Consolidated Standards of Reporting Trials
(CONSORT) statement extension to cluster RCTs [39].
A cluster design was chosen to avoid the possibility of
contamination across arms. If a GP was treating both
intervention and control patients, they may find it diffi-
cult to behave differently towards each group [40]. The
trial will be conducted in primary care with GP practices
as the unit of randomisation. The intervention will be
delivered at the GP level while the unit of analysis will
be the individual patient, adjusting for clustering. A
mixed methods process evaluation and economic analysis
will also be conducted.
Study population
Practices will be eligible to participate if:
 They have at least 300 patients aged ≥65 years on
their patient panel. This is based on the need to
identify at least 15 patients per practice who are
receiving ≥15 repeat medicines (which is 5% of
people aged ≥65 years in the national Primary Care
Reimbursement Service (PCRS) pharmacy-
dispensing database [7]).
 They use Socrates or Health One as a PMS system
(to enable use of the software patient finder tool).
Patients will be considered eligible if:
 They are aged ≥65 years.
 They are being prescribed 15 or more repeat
medicines, which is a measure of both significant
polypharmacy and complex multimorbidity [41]. A
repeat medicine is defined as any item with an ATC
code for which the patient is currently in receipt of
Table 5 SPPiRE Pilot Results
Pilot Component Problem Change
Finder tool Over identification of patients • Include only items with unique ATC code
• Include only items listed as “current”
Educational videos Not fully watched by all GPs due to time constraint • Content condensed
• Focus on demonstrating review process
Web-guided medication review Not fully completed by all GPs • Website layout modified
• Instructions more explicit
• Recommendation to allow for more time
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a prescription of and is classified by the PMS as a
“repeat” item.
Practices will be excluded if:
 They are currently involved in a medication
management or prescribing trial.
Patients will be excluded if:
 They are unable to give informed consent, as judged
by their GP.
 They are unable to attend the practice for a face-to-
face medication review.
 They have previously taken part in the OPTI-
SCRIPT intervention.
Recruitment and allocation
Eligible practices (see eligibility criteria above) will be
identified through the Health Research Board Primary
Care Clinical Trials Network, Ireland (http://primarycar
etrials.ie/) and invited to participate by formal letter, in-
cluding letter of agreement to participate and study in-
formation leaflets detailing the steps of the intervention.
Practices will identify patients aged 65 years and over
who are currently prescribed 15 or more repeat
medicines using the patient finder tool, which will be
integrated into practice management software in par-
ticipating practices. The research team will assist prac-
tices in recruiting eligible patients, who will be sent
invitation letters (on practice headed paper) with con-
sent forms, information leaflets and questionnaires. Based
on recent analysis of prescribing trends in Ireland, we
anticipate that most included practices will have at
least 15 eligible patients [7]. In larger practices with
more than 40 eligible patients, we will randomly se-
lect 40 patients to invite, based on the OPTI-SCRIPT
response rate [28]. Control practices will receive €30
per recruited patient and intervention practices €60
per recruited patient to reflect some of the costs
involved in taking part in the study.
Baseline data collection will occur prior to practice allo-
cation by review of patient prescriptions and questionnaires
(see outcomes and methods for data collection below).
Recruited practices will be randomly allocated, using mini-
misation and randomisation software, by an independent
third party (Fig. 2). Minimisation will ensure balance
between the groups [39, 40] in terms of practice size
(number of whole-time-equivalent GPs) and location
(urban versus rural). An “urban” practice is defined as
being located in an area with a population of at least
5000 people, has most of its patients within a rela-
tively small geographical area and have ready access
some hospital facilities [42]. Considering the nature of
the intervention, it is not possible to blind GPs or
participants to the intervention.
The intervention
The content of the SPPiRE intervention was developed
based on the OPTI-SCRIPT trial, emerging evidence and
results from the SPPiRE pilot and contains the following
elements:
1) Training videos which demonstrate how to
perform a SPPiRE medication review and
describe the underlying evidence on polypharmacy,
common potentially inappropriate prescriptions in
older people, multimorbidity and treatment
burden. The videos also provide guidance on
establishing treatment burden and supporting
patients to express their priorities, based on
recommendations in the NICE multimorbidity
guideline [6].
2) An online medication review template (see Fig. 3)
which provides a structured process and links to
alternative strategies for each identified PIP. The GP
will be guided to:
a. Screen the prescription for PIP, including the
requirement for monitoring and if duplicate drug
classes are present.
b. Assess the patient’s treatment priorities and
consider whether on-going symptoms may
represent adverse drug reactions.
c. Review each medicine with the patient assessing
the effectiveness of symptomatic treatment, the
relative harms and benefits of preventative
treatment, the presence of adverse drug reactions
and whether each medicine is being taken as
prescribed.
d. Agree all changes with the patient, taking into
account their treatment priorities and considering
suggested treatment alternatives for identified PIP.
e. Print out a summary document which will
be generated upon completion of the review.
This will outline all changes and any action
that needs to be taken, including the need
for blood monitoring if indicated.
Any medication changes will be at the discretion of
the prescribing GP, weighing up the risks and benefits
and incorporating patient preference.
The control arm will continue to deliver usual care for
the 6-month study duration. Usual care will vary from
practice to practice, and differences in repeat prescribing
policies between clusters will be identified and described
using a baseline practice profile questionnaire. Following
6-month data collection and completion of the RCT,
McCarthy et al. Implementation Science  (2017) 12:99 Page 7 of 13
Fig. 3 SPPiRE medication review process. Abbreviations: PIP potentially inappropriate prescription, ADR adverse drug reaction
Fig. 2 Flow of practices and patients through RCT
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control arm GPs will be invited to participate in the
intervention as outlined above. No further RCT data will
be collected from participants on trial completion at
6 months. However, we will ask intervention practices to
submit prescription data at 12 months to examine
whether changes in prescriptions have been maintained.
Contemporaneous national control–PCRS dataset
We will also analyse national prescription patterns via
the Health Service Executive (HSE) primary care reim-
bursement service (PCRS) prescription database. This is
a national prescribing database based on GP and phar-
macy claims in a number of community schemes, in-
cluding the General Medical Services (GMS) scheme. In
2014, 70% of people aged over 65 years in Ireland were
covered by the GMS scheme and so their prescription
data are captured in the PCRS database [43]. Anon-
ymised data from the PCRS GMS database can be used
to provide a contemporary national control. Compari-
sons to previous national prescribing patterns for those
aged 65 years and over being prescribed 15 or more
medicines will determine if there has been a change over
time at the population level [7].
Outcomes measures
Outcome measures pertain to the individual patient level
and have been specifically chosen to reflect the potential
effects of the intervention and to incorporate the patient
perspective. Baseline data will be collected prior to allo-
cation using the PMS, patient questionnaires and a
practice profile questionnaire. Follow-up data will be
collected 6 months following completion of each medi-
cation review in intervention patients through review of
the PMS and patient questionnaires and 6 months
following the median date of all the medication review
dates in control practices.
Primary outcomes:
 Proportion of patients with any PIP (see Tables 2,
3, and 4)
 Mean number of repeat medications, defined as any
medicine with an ATC code for which the patient is
currently in receipt of a repeat prescription.
Secondary outcomes:
 Reduction in proportion of patients with 15 or more
medicines (100% at baseline)
 Medication changes
○ Number of medications stopped (per patient and
absolute number in intervention versus control)
○ Numbers of medications started (per patient and
absolute number in intervention versus control)
○ Reduction in the number of PIP (per patient and
absolute number in intervention versus control)
○ Proportion of patients with any reduction in PIP
 Multimorbidity Treatment Burden Questionnaire
(MTBQ) [44]
 Health related quality of life (EQ5D-5L) [45]
 Revised Patients’ Attitudes Towards Deprescribing
(rPATD) [46]
 Health service utilisation per patient (based on chart
data and collected on both time periods (baseline
and 6 months post-intervention completion), at
study completion by the research team
○ Number of GP/practice nurse visits
○ Number of out-of-hours visits
○ Number of Accident & Emergency (A&E) visits
○ Number of emergency hospital admissions and
reason for admission
○ Number of in-patient days
○ Number of out-patient visits
 Patient-reported adverse drug withdrawal events
(ADWEs) from follow-up patient questionnaire
(defined as either recurrence of the condition for
which the drug was prescribed or a physiologic
reaction to drug withdrawal.) [47, 48]
Plan of analysis
Descriptive statistics (proportions, means) will be used
to evaluate differences in baseline characteristics be-
tween participating GP practices and patients in the two
arms of the trial. The primary analysis will be carried
out using multilevel modelling. The primary outcome
measure, proportion of patients with or without a PIP,
will be a binary outcome measure and will be compared
between treatment arms using random effects logistic
regression with individuals as the unit of analysis and
the practice included as the random effect.
The second primary outcome measure, number of re-
peat medications, will be assessed using a random effect
Poisson regression with the individual as the unit of ana-
lysis and the practice included as the random effect to
control for the effects of clustering. Incidence rate ratios
(IRR) and 95% confidence intervals (CI) will be presented.
All analysis will be conducted under the intention-to-treat
principle as this is a pragmatic trial [39].
Sample size
Sample size for the primary outcome (proportion with
PIP) is based on a prevalence of approximately 40% for
PIP in this population [7]. To reduce this to 20%
requires a sample size of 240 patients. The sample size
also needs to be adjusted to reflect the assumption that
individual outcomes are not independent of each other,
as participants in the same cluster may respond in the
same way. Hence, an intra-cluster correlation coefficient
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(ICC) of 0.025 will be used. This was also used in the
OPTI-SCRIPT study and was based on an observational
study of an elderly cohort in the HRB Centre for
Primary Care Research [49]. This gives a design effect
size of 1.35, thus inflating the sample to 324 patients
from 22 practices. An equal cluster size of 15 patients
per practice has been assumed.
All the patients in this study will be selected on the
basis of receiving 15 or more repeat medicines on their
prescription. Existing data from the Irish national pre-
scribing database (HSE-PCRS) highlights that in those
aged 65 years and over on 15 or more repeat medicines,
the mean number of medicines is 17.4 (SD 2.69) [7]. A
meta-analysis of deprescribing trials reported a differ-
ence between treatment groups of 0.4 medicines where
the mean number of medicines was 7.4 [50]. We are
targeting patients on at least 15 repeat medicines and
for primary outcome, number of repeat medications, will
test for a mean difference of one medicine between the
intervention and control group and this would require a
sample size of 306 patients. This is inflated by the design
effect size outlined above (1.35) to give a sample of 413
patients from 28 practices.
Factoring in a loss to follow-up of approximately 10%
(for primary outcomes, based on chart data) and using the
higher numbers required to demonstrate a significant re-
duction in mean number of repeat medicines, a total of 30
GP practices and 450 patients will be required.
Process evaluation
SPPiRE is a complex intervention as there are several
different interacting components and a degree of flexibil-
ity or tailoring to the local environment [31]. The aim of
the process evaluation will be to explore the effect of the
intervention and how it was implemented. It will com-
bine both quantitative and qualitative data and follow a
framework specific for cluster RCTs [51].
Study population
All participating practices and a purposive sample of
patients will be invited to participate by letter and
follow-up telephone call.
Process evaluation data collection
Quantitative data will be compiled from a number of
sources including completed questionnaires, researcher
logs and evaluation forms and website usage data. Quali-
tative data will be collected from patients and GPs and
other practice staff using semi-structured interviews.
The number of interviews needed to reach data satur-
ation (where no new themes emerge) will be considered
alongside feasibility issues (resources and timing), but a
sample of 15–20 is proposed [45].
These interviews will be conducted either in person or
via telephone. Telephone interviewing is generally used
where time or costs are issues, and evidence suggests
there is little difference in the answers obtained this way
[52]. All interviews will be audio recorded (on loud
speaker for telephone interviews).
Process evaluation measures:
 Use of the intervention software
 Clinical/ prescribing decision made, e.g. stop or start
medicine, refer for monitoring blood test
 Reported primary reason for decision made, e.g.
risks outweigh benefits, patient preference, hospital/
consultant initiated
 Whether assessment of patient priorities resulted in
medication change and which priorities were
associated with most change
 Immediate pre- and post-intervention prescription
Process evaluation data analysis
Quantitative data will be summarised using descriptive
statistics. All interviews will be transcribed verbatim and
broad themes and sub-themes identified using thematic
analysis. NVivo 10 (QSR International) will be used to
assist with organising the data for analysis.
Economic evaluation
The health economic analysis will consist of a trial-
based economic evaluation of the proposed intervention
and will incorporate both cost effectiveness analysis and
cost utility analysis. The evaluation will be undertaken in
a manner consistent with guidelines issued by the Health
Information and Quality Authority (HIQA) in Ireland
[53]. Evidence collected on resource use, costs and
health outcome measures will provide the basis for the
evaluation over the trial follow-up period. With respect
to costing, a publicly funded health service perspective
will be adopted. That is, resource use associated with
delivery of the proposed intervention will be measured
and costed, as will other health service resource use by
patients over the course of the trial. As detailed above,
significant attention will be paid to collecting relevant
data on health outcomes alongside the trial for the pur-
poses of the clinical effectiveness analysis. For the cost
effectiveness analysis, effectiveness will be evaluated on
the basis of the number of PIPs averted. For the cost
utility analysis, effectiveness will be evaluated in terms of
quality adjusted life years (QALYs), which will be
estimated based on responses to the EuroQol EQ-5D-5L
instrument [45]. An incremental analysis will be under-
taken to provide information on the marginal costs and
effects of the intervention relative to the control through
the calculation of incremental cost effectiveness ratios
(ICERs). The statistical analysis will be conducted in
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accordance with current guidelines for economic evalu-
ation alongside cluster RCTs [53]. That is, we will adopt
multilevel statistical techniques which recognise both
the clustering and correlation in the cost and effect data.
Uncertainty in the economic analysis will be addressed
by estimating cost effectiveness acceptability curves
(CEACs), which link the probability of treatment being
cost effective to a range of potential threshold values (λ)
that a health system may be willing to pay.
Data management and protection
All patients will provide informed consent and will be
known to the research team by study ID only. The pa-
tient’s GP remains responsible for all treatment decisions
made. Informed consent will be sought from all GPs
participating in the study. All data collected, including
interview transcripts for the process evaluation, will be
stored on a secure, password protected network drive.
Monitoring and participant safety
A Trial Steering Committee (TSC) comprising an inde-
pendent chair and two other independent members, one
of whom is a lay member representing the patient and
public perspective, has been established and will oversee
the progress of the trial and adherence to the study
protocol. It was agreed by the TSC that given the low
risk nature of the trial, lack of interim data and relatively
short term follow-up, that there is no need for the estab-
lishment of a Data Monitoring Committee.
A formal process has been developed to capture any po-
tential adverse events related to discontinuing medication.
Recruited practices will be instructed in the practice re-
cruitment leaflet on how to report any suspected adverse
effects from deprescribing. Any adverse events will also be
captured by a chart review at follow-up data collection.
An assessment on likely causality will then be made using
an adapted drug withdrawal probability scale [48]. Patient-
reported ADWEs will also be collected as a secondary
outcome measures in the follow-up patient questionnaire,
6 months after intervention completion. Any patient
safety concerns arising during the course of the trial,
including at baseline data collection, will be brought to
the attention of the Trial Steering Committee.
Discussion
Polypharmacy is frequently cited as an area of major
concern by patients with multimorbidity [54, 55]. The
most appropriate course of action when deciding
whether to continue to prescribe is often not readily ap-
parent but should include some assessment of the rela-
tive harms and benefits of treatment, in the context of
the patient’s priorities [56]. We propose that an indivi-
dualised structured medication review, where depre-
scribing is considered alongside prescribing, and where
there is active engagement with patients on their views
on treatment is essential to tackling polypharmacy and
inappropriate prescribing.
The SPPiRE intervention provides structure and assist-
ance in performing medication reviews by aiding GPs in
identifying PIP, suggesting alternatives and encouraging
care to be tailored to individual patient priorities.
Strengths of this study include the pragmatic study de-
sign, incorporation of clinical guidelines and the fact that
the intervention can be delivered by the patient’s GP.
Currently, there is no provision under the GP reim-
bursement scheme in Ireland for a medication review
for older patients and the potential and costs of a
system-wide implementation of the SPPiRE intervention
in Irish primary care will be explored in the process and
economic evaluations.
Limitations of the study include the possibility of con-
tamination of the control group where GPs also identify
patients on 15 or more medicines using the patient
finder tool and may treat these patients differently or
provide more consideration than usual when renewing
prescriptions. This will be explored in the process evalu-
ation. Patients will also be encouraged to think about
their treatment burden and attitudes towards deprescrib-
ing when completing baseline questionnaires and may
be influenced to discuss their medications with their GP.
Secondly, given the nature of the intervention it is not
possible to blind patients, GPs or study personnel to the
intervention. This has been addressed somewhat by
using robust, objective primary outcome measures
where there is little room for subjective opinion (number
of repeat medicines and number of patients with any
pre-defined PIP).
In summary, this study will provide evidence on the
effectiveness and acceptability of a complex intervention
designed to support GPs improve prescribing and reduce
polypharmacy for older patients with multimorbidity
and significant polypharmacy in Irish primary care.
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